CN102824634B - 表达猪圆环病毒2型Cap蛋白的重组猪痘病毒载体疫苗及其制备方法 - Google Patents
表达猪圆环病毒2型Cap蛋白的重组猪痘病毒载体疫苗及其制备方法 Download PDFInfo
- Publication number
- CN102824634B CN102824634B CN201210340309.6A CN201210340309A CN102824634B CN 102824634 B CN102824634 B CN 102824634B CN 201210340309 A CN201210340309 A CN 201210340309A CN 102824634 B CN102824634 B CN 102824634B
- Authority
- CN
- China
- Prior art keywords
- cap
- virus
- swinepox virus
- gene
- recombinant swinepox
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000700565 Swinepox virus Species 0.000 title claims abstract description 73
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 39
- 229960005486 vaccine Drugs 0.000 title claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 9
- 241000202347 Porcine circovirus Species 0.000 title abstract description 3
- 238000001814 protein method Methods 0.000 title 1
- 239000002671 adjuvant Substances 0.000 claims abstract description 5
- 241000282898 Sus scrofa Species 0.000 claims description 63
- 241000700605 Viruses Species 0.000 claims description 43
- 241001673669 Porcine circovirus 2 Species 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 24
- 101150044789 Cap gene Proteins 0.000 claims description 22
- 239000013605 shuttle vector Substances 0.000 claims description 21
- 230000009471 action Effects 0.000 claims description 13
- 239000013553 cell monolayer Substances 0.000 claims description 13
- 238000000746 purification Methods 0.000 claims description 12
- 238000011081 inoculation Methods 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000001638 lipofection Methods 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000002398 materia medica Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 17
- 230000001681 protective effect Effects 0.000 abstract description 3
- 239000000969 carrier Substances 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 41
- 230000036039 immunity Effects 0.000 description 20
- 231100000614 poison Toxicity 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 14
- 239000003440 toxic substance Substances 0.000 description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 230000009182 swimming Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000036285 pathological change Effects 0.000 description 10
- 231100000915 pathological change Toxicity 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 241000282887 Suidae Species 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001582888 Lobus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 241000305761 Calidris canutus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000358276 Cryptoprocta ferox Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 208000028489 postweaning multisystemic wasting syndrome Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
组号 | 个数 | 免疫情况 | 大体病变 | 显微病变 |
1 | 8 | rSPV-Cap | 2.52 ± 0.49 | 2.80 ± 0.32 |
2 | 8 | wtSPV | 7.43 ± 0.68 | 5.28 ± 0.33 |
3 | 4 | PBS | 7.87 ± 0.73 | 5.63 ± 0.62 |
4 | 4 | ------ | 0.00 ± 0.00 | 0.00 ± 0.00 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210340309.6A CN102824634B (zh) | 2012-09-14 | 2012-09-14 | 表达猪圆环病毒2型Cap蛋白的重组猪痘病毒载体疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210340309.6A CN102824634B (zh) | 2012-09-14 | 2012-09-14 | 表达猪圆环病毒2型Cap蛋白的重组猪痘病毒载体疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102824634A CN102824634A (zh) | 2012-12-19 |
CN102824634B true CN102824634B (zh) | 2014-03-19 |
Family
ID=47328080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210340309.6A Expired - Fee Related CN102824634B (zh) | 2012-09-14 | 2012-09-14 | 表达猪圆环病毒2型Cap蛋白的重组猪痘病毒载体疫苗及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102824634B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104587459B (zh) * | 2014-11-10 | 2017-08-25 | 邓舜洲 | 表达猪圆环病毒2型衣壳蛋白重组猪痘病毒载体疫苗 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1769435A (zh) * | 2005-04-07 | 2006-05-10 | 南京农业大学 | 猪ⅱ型圆环病毒重组腺病毒和疫苗 |
CN101932700A (zh) * | 2007-12-21 | 2010-12-29 | 惠氏有限责任公司 | 对猪进行抗猪圆环病毒免疫的方法和组合物 |
CN102198268A (zh) * | 2011-03-29 | 2011-09-28 | 范红结 | 表达马链球菌兽疫亚种类m蛋白的重组猪痘病毒载体疫苗 |
CN102296089A (zh) * | 2011-04-20 | 2011-12-28 | 中国兽医药品监察所 | 高效制备猪圆环病毒2型空衣壳粒子的方法 |
CN102333876A (zh) * | 2008-12-15 | 2012-01-25 | 维克托根有限公司 | 基于pcv 2的用于治疗猪的方法和组合物 |
CN102517331A (zh) * | 2011-12-26 | 2012-06-27 | 武汉中博生物股份有限公司 | 一种猪圆环病毒2型亚单位疫苗及其制备方法和其应用 |
-
2012
- 2012-09-14 CN CN201210340309.6A patent/CN102824634B/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1769435A (zh) * | 2005-04-07 | 2006-05-10 | 南京农业大学 | 猪ⅱ型圆环病毒重组腺病毒和疫苗 |
CN101932700A (zh) * | 2007-12-21 | 2010-12-29 | 惠氏有限责任公司 | 对猪进行抗猪圆环病毒免疫的方法和组合物 |
CN102333876A (zh) * | 2008-12-15 | 2012-01-25 | 维克托根有限公司 | 基于pcv 2的用于治疗猪的方法和组合物 |
CN102198268A (zh) * | 2011-03-29 | 2011-09-28 | 范红结 | 表达马链球菌兽疫亚种类m蛋白的重组猪痘病毒载体疫苗 |
CN102296089A (zh) * | 2011-04-20 | 2011-12-28 | 中国兽医药品监察所 | 高效制备猪圆环病毒2型空衣壳粒子的方法 |
CN102517331A (zh) * | 2011-12-26 | 2012-06-27 | 武汉中博生物股份有限公司 | 一种猪圆环病毒2型亚单位疫苗及其制备方法和其应用 |
Non-Patent Citations (4)
Title |
---|
猪圆环病毒2型免疫学研究进展;王宪文等;《畜牧与兽医》;20110430;第43卷(第4期);第94-96页 * |
猪圆环病毒病及其生物制品学的研究进展;郎洪武等;《中国兽医科学》;20120531;第42卷(第5期);第545-550页 * |
王宪文等.猪圆环病毒2型免疫学研究进展.《畜牧与兽医》.2011,第43卷(第4期),第94-96页. |
郎洪武等.猪圆环病毒病及其生物制品学的研究进展.《中国兽医科学》.2012,第42卷(第5期),第545-550页. |
Also Published As
Publication number | Publication date |
---|---|
CN102824634A (zh) | 2012-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107815441B (zh) | 一种ⅱ型伪狂犬病毒减毒株及其制备方法和应用 | |
US8277814B2 (en) | Avian Astrovirus | |
CN102198268B (zh) | 表达马链球菌兽疫亚种类m蛋白的重组猪痘病毒载体疫苗 | |
CN109195623A (zh) | 嵌合型猪圆环病毒2型(pcv2)疫苗 | |
CN107184969A (zh) | 一种a型赛尼卡谷病毒灭活疫苗及其制备方法和应用 | |
CN107841507A (zh) | 一种高效表达的猪圆环病毒2型Cap‑穿膜肽融合蛋白基因及其应用 | |
WO2020258757A1 (zh) | 一种突变株3型鸭甲肝病毒ch-p60-117c株及构建方法 | |
CN104059889B (zh) | 伪狂犬病病毒变异株双基因缺失毒株及其构建方法和应用 | |
CN110423269A (zh) | 一种串联优势表位的重组猪圆环病毒2型Cap蛋白及其应用 | |
CN104561049A (zh) | 一种表达猪细小病毒vp2蛋白的重组杆状病毒及制备方法与应用 | |
CN109321534A (zh) | 一种重组基因viii型新城疫病毒弱毒株 | |
CN103509761B (zh) | 表达猪圆环病毒ⅱ型orf2基因的重组猪伪狂犬病毒毒株及其制备方法 | |
CN108101967B (zh) | Ⅰ群血清4型禽腺病毒基因工程亚单位疫苗、制备方法及其应用 | |
CN113491767A (zh) | 鸭圆环病毒病、新型鸭呼肠弧病毒病、鸭病毒性肝炎三联灭活疫苗及其制备方法 | |
CN109303916A (zh) | 焦亡相关蛋白gsdmd在制备菌蜕疫苗中的应用 | |
CN112500458B (zh) | 鸡传染性法氏囊病病毒新型变异株亚单位疫苗、其制备方法及应用 | |
CN110305852A (zh) | 表达猪流行性腹泻病毒s1基因重组伪狂犬病病毒的构建 | |
CN113384692A (zh) | 鸭呼肠弧病毒、鸭圆环病毒二联灭活疫苗及其制备方法 | |
CN105441393A (zh) | 鸡传染性法氏囊病超强毒df-1细胞适应株及其应用 | |
CN111647568A (zh) | 鸡传染性法氏囊病病毒新型变异株反向遗传疫苗株及其应用 | |
CN104436187A (zh) | 表达兔病毒性出血症病毒vp60蛋白疫苗 | |
CN102824634B (zh) | 表达猪圆环病毒2型Cap蛋白的重组猪痘病毒载体疫苗及其制备方法 | |
CN105802918B (zh) | 鸡肾型传染性支气管炎病毒毒株及其疫苗组合物、制备方法和应用 | |
CN109136200A (zh) | 一种重组传染性造血器官坏死病毒及其构建方法与应用 | |
CN103409374A (zh) | 猪圆环病毒病、猪链球菌病和副猪嗜血杆菌病三联灭活疫苗及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LIN HUIXING LU CHENGPING Effective date: 20140408 Owner name: NANJING AGRICULTURAL UNIVERSITY Free format text: FORMER OWNER: FAN HONGJIE Effective date: 20140408 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Fan Hongjie Inventor after: Zhou Hong Inventor after: Lin Huixing Inventor after: Lu Chengping Inventor before: Fan Hongjie Inventor before: Lin Huixing Inventor before: Lu Chengping |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FAN HONGJIE LIN HUIXING LU CHENGPING TO: FAN HONGJIE ZHOU HONG LIN HUIXING LU CHENGPING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140408 Address after: Nanjing City, Jiangsu Province, Nanjing Agricultural University No. 1 210095 Weigang Patentee after: NANJING AGRICULTURAL University Address before: Nanjing City, Jiangsu Province, No. 1 210095 Weigang Patentee before: Fan Hongjie Patentee before: Lin Huixing Patentee before: Lu Chengping |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140319 Termination date: 20210914 |
|
CF01 | Termination of patent right due to non-payment of annual fee |